Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide
2. Rta 408
3. Rta-408
1. 1474034-05-3
2. Rta-408
3. Rta 408
4. Nrf1-activator-1
5. Omaveloxolone [inn]
6. Rta408
7. G69z98951q
8. N-[(4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
9. Propanamide, N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoro-
10. N-(2-cyano-3,12-dioxo-28-noroleana-1,9(11)-dien-17-yl)-2,2-difluoropropanamide
11. Unii-g69z98951q
12. Omaveloxolone (usan/inn)
13. Omaveloxolone [usan]
14. Omaveloxolone [who-dd]
15. Gtpl7573
16. Chembl4303525
17. Schembl15349371
18. Ex-a541
19. Dtxsid101138251
20. Bcp28609
21. Mfcd28167769
22. Akos037648676
23. Zinc144682962
24. Db12513
25. Bs-15146
26. Hy-12212
27. N-(11-cyano-2,2,6a,6b,9,9,12a-heptmethyl-10,14-dioxo-1,3,4,5,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydro-2h-picen-4a-yl)-2-2-difluoropropionamide
28. D10964
29. Rta408; Rta408; Rta-408;nrf1-activator-1
30. Q21098900
31. N-((4as,6ar,6bs,8ar,12as,14ar,14bs)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide
Molecular Weight | 554.7 g/mol |
---|---|
Molecular Formula | C33H44F2N2O3 |
XLogP3 | 6.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 554.33199959 g/mol |
Monoisotopic Mass | 554.33199959 g/mol |
Topological Polar Surface Area | 87 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 1320 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 7 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
NDC Package Code : 50683-0525
Start Marketing Date : 2023-02-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42052-1702
Start Marketing Date : 2024-07-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50683-0525
Start Marketing Date : 2023-02-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 42052-1702
Start Marketing Date : 2024-07-05
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Details:
Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2025
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BIIB141 PK Comparison Capsules Vs Yogurt In Healthy Adults 18-55
Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 13, 2025
Details:
Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 01, 2025
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2025
Details:
Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2024
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2024
Details:
Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Skyclarys
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2024
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Gets European Commission Approval for SKYCLARYS® to Treat Friedreich's Ataxia
Details : Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Product Name : Skyclarys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2024
Details:
Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Skyclarys
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2023
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Trea...
Details : Skyclarys (omaveloxolone) is an oral Nuclear factor erythroid-derived 2 (Nrf2) pathway activator. It is approved for the treatment of patients with Friedreich’s ataxia.
Product Name : Skyclarys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2023
Details:
Skyclarys (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Skyclarys
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2023
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Issues Positive Opinion for Biogen's SKYCLARYS® (omaveloxolone), the First Therapy to Treat ...
Details : Skyclarys (omaveloxolone) is an oral, once-daily medication indicated for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older.
Product Name : Skyclarys
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2023
Details:
Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Friedreich Ataxia.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 26, 2023
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 26, 2023
Details:
Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Biogen
Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million
Deal Type: Acquisition September 26, 2023
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Biogen Completes Acquisition of Reata Pharmaceuticals
Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $7,300.0 million
September 26, 2023
Details:
Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Lead Product(s): Omaveloxolone,Inapplicable
Therapeutic Area: Genetic Disease Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Biogen
Deal Size: $7,300.0 million Upfront Cash: $7,300.0 million
Deal Type: Acquisition July 28, 2023
Lead Product(s) : Omaveloxolone,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : $7,300.0 million
Deal Type : Acquisition
Biogen to Acquire Reata Pharmaceuticals
Details : Through the acquisition, Biogen bolster its neuromuscular and rare disease portfolio by gaining FDA-approved Skyclarys (omaveloxolone), the first and only approved treatment for Friedreich’s ataxia (FA) in the United States.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $7,300.0 million
July 28, 2023
Details:
Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Omaveloxolone,Moxifloxacin
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Celerion | Q2 Solutions
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 03, 2023
Lead Product(s) : Omaveloxolone,Moxifloxacin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Celerion | Q2 Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
A TQTc Study for Omaveloxolone
Details : Omaveloxolone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 03, 2023
RLD : Yes
TE Code :
Brand Name : SKYCLARYS
Dosage Form : CAPSULE;ORAL
Dosage Strength : 50MG
Approval Date : 2023-02-28
Application Number : 216718
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
92
PharmaCompass offers a list of Omaveloxolone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Omaveloxolone manufacturer or Omaveloxolone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Omaveloxolone manufacturer or Omaveloxolone supplier.
PharmaCompass also assists you with knowing the Omaveloxolone API Price utilized in the formulation of products. Omaveloxolone API Price is not always fixed or binding as the Omaveloxolone Price is obtained through a variety of data sources. The Omaveloxolone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Omaveloxolone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Omaveloxolone, including repackagers and relabelers. The FDA regulates Omaveloxolone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Omaveloxolone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Omaveloxolone supplier is an individual or a company that provides Omaveloxolone active pharmaceutical ingredient (API) or Omaveloxolone finished formulations upon request. The Omaveloxolone suppliers may include Omaveloxolone API manufacturers, exporters, distributors and traders.
click here to find a list of Omaveloxolone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Omaveloxolone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Omaveloxolone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Omaveloxolone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Omaveloxolone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Omaveloxolone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Omaveloxolone suppliers with NDC on PharmaCompass.
Omaveloxolone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Omaveloxolone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Omaveloxolone GMP manufacturer or Omaveloxolone GMP API supplier for your needs.
A Omaveloxolone CoA (Certificate of Analysis) is a formal document that attests to Omaveloxolone's compliance with Omaveloxolone specifications and serves as a tool for batch-level quality control.
Omaveloxolone CoA mostly includes findings from lab analyses of a specific batch. For each Omaveloxolone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Omaveloxolone may be tested according to a variety of international standards, such as European Pharmacopoeia (Omaveloxolone EP), Omaveloxolone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Omaveloxolone USP).